PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26628971-12 2015 Similarly, levels of IL-6 and TNF-alpha were increased in spontaneous hypertension group and decreased in berberine group. Berberine 106-115 tumor necrosis factor Rattus norvegicus 30-39 26628971-15 2015 CONCLUSION: Berberine plays a protective role in vascular endothelial cell injury through inhibiting apoptosis and expression of TLR4, Myd88, NF-kappaB, IL-6 and TNF-alpha. Berberine 12-21 tumor necrosis factor Rattus norvegicus 162-171 34265298-4 2021 The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-kappaB, tumor necrosis factor-alpha, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-gamma. Berberine 24-27 tumor necrosis factor Rattus norvegicus 205-232 34930229-11 2021 BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1beta and tumor necrosis factor alpha) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Berberine 0-3 tumor necrosis factor Rattus norvegicus 239-266 34600570-9 2021 Our outcomes of TNF-a, IL-1B, and MDA evaluation show a significant ameliorating effect of the Berberine (BBR) and BBR-loaded micelles in pretreated groups. Berberine 106-109 tumor necrosis factor Rattus norvegicus 16-21 34600570-9 2021 Our outcomes of TNF-a, IL-1B, and MDA evaluation show a significant ameliorating effect of the Berberine (BBR) and BBR-loaded micelles in pretreated groups. Berberine 115-118 tumor necrosis factor Rattus norvegicus 16-21 34483445-6 2021 Berberine significantly counteracted (P<0.05) the increase of TNF-alpha, IL-6, caspase-3 and BAX and counteracted the increase in plasma cTn-T and serum MDA. Berberine 0-9 tumor necrosis factor Rattus norvegicus 62-71 34211579-13 2021 Compared with the model group, the body mass of rats in the berberine group was significantly increased (P < 0.05); the general morphology and pathological changes of colon tissue were significantly improved; CMDI score, serum and colon tissue IL-1beta, TNF-alpha content, and protein expression were decreased significantly (P < 0.05); and IL-4 content and protein expression increased significantly (P < 0.05). Berberine 60-69 tumor necrosis factor Rattus norvegicus 254-263 34094026-5 2021 Results: The results showed that ALT, AST, lipid profile, insulin, glucose, MDA, and TNF-alpha were significantly improved in high-fat rats treated with Berberine/ Sitagliptin compared with HF and Sitagliptin, and Berberine alone groups. Berberine 153-162 tumor necrosis factor Rattus norvegicus 85-94 34094026-5 2021 Results: The results showed that ALT, AST, lipid profile, insulin, glucose, MDA, and TNF-alpha were significantly improved in high-fat rats treated with Berberine/ Sitagliptin compared with HF and Sitagliptin, and Berberine alone groups. Berberine 214-223 tumor necrosis factor Rattus norvegicus 85-94 35121005-8 2022 It was observed that BTZ caused inflammation by triggering NF-kappaB, TNF-alpha, IL-1beta and IL-6 cytokines, on the other hand, with BBR treatment, these cytokines were suppressed and inflammation was alleviated. Berberine 134-137 tumor necrosis factor Rattus norvegicus 70-79 34984656-9 2022 Pretreatment of rats with berberine nanocomplexes significantly reduced the paw edema in inflamed rat paws, decreased the production of nitrite and TNF-alpha in plasma and repressed the mRNA expression levels of TNF-alpha and IL-1beta in paw tissue in comparison to berberine per se treated rats. Berberine 26-35 tumor necrosis factor Rattus norvegicus 148-157 34984656-9 2022 Pretreatment of rats with berberine nanocomplexes significantly reduced the paw edema in inflamed rat paws, decreased the production of nitrite and TNF-alpha in plasma and repressed the mRNA expression levels of TNF-alpha and IL-1beta in paw tissue in comparison to berberine per se treated rats. Berberine 26-35 tumor necrosis factor Rattus norvegicus 212-221 33376517-11 2021 This prophylactic effect of berberine was associated with reduced phosphorylation of p65 and with decreased levels of pro-inflammatory cytokines IL-6 and TNF-alpha. Berberine 28-37 tumor necrosis factor Rattus norvegicus 154-163 34025574-15 2021 Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-kappaB and TNF-alpha induced in IGT rats (P<0.05). Berberine 0-9 tumor necrosis factor Rattus norvegicus 191-200 33682914-9 2022 Meanwhile, berberine reversed elevated expression of cytokines interleukin-1beta and TNF-alpha in the serum and downregulated nuclear factor kappaB expression. Berberine 11-20 tumor necrosis factor Rattus norvegicus 85-94 33626003-10 2020 RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues. Berberine 9-12 tumor necrosis factor Rattus norvegicus 207-216 33407557-13 2021 CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3. Berberine 13-16 tumor necrosis factor Rattus norvegicus 159-168 33506010-10 2021 Moreover, the TNF-alpha decreased significantly accompanied by the increase of berberine, chlorogenic acid, jatrorrhizine, palmatine, evodin, and evodiamine in serum (negative correlation, p < 0.05). Berberine 79-88 tumor necrosis factor Rattus norvegicus 14-23 32972060-13 2020 Conclusions: Berberine can improve myocardial injury and cardiac function in sepsis rats, the mechanism is considered to be related to that it can inhibit the activation of TLR4/NF-kappaB signaling pathway induced by LPS and further reducing the production of TNF-alpha and IL-1beta. Berberine 13-22 tumor necrosis factor Rattus norvegicus 260-269 32961234-12 2020 Berberine in a dose-dependent manner raised hepatic ApoM mRNA and plasma ApoM level, but decreased septic hyperglycemia, insulin resistance and plasma TNF-alpha and IL-1beta levels. Berberine 0-9 tumor necrosis factor Rattus norvegicus 151-160 32888284-8 2021 Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group. Berberine 0-9 tumor necrosis factor Rattus norvegicus 90-117 32888284-8 2021 Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group. Berberine 0-9 tumor necrosis factor Rattus norvegicus 119-128 32888284-9 2021 Compared with the model group, berberine inhibited the proliferation and migration of VSMCs in vitro, and reduced tumor growth factor-beta1 (TGF-beta1), IL-6, and TNF-alpha levels. Berberine 31-40 tumor necrosis factor Rattus norvegicus 163-172 32606611-6 2020 After four weeks of BBR intervention, the plaque area in the AS + DH + BBR group was reduced with decreased foam cells and macrophage infiltration, and decreased levels of TNF-alpha and IL-1beta, whereas LC3-II protein expression was increased and P62 protein expression was decreased in the AS + DH + BBR group when compared to AS + DH group. Berberine 20-23 tumor necrosis factor Rattus norvegicus 172-181 31413530-10 2019 Oral administration of BBR inhibited the NF-kappaB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-beta), and improved the terminal ileum tissue inflammation. Berberine 23-26 tumor necrosis factor Rattus norvegicus 186-213 32606611-7 2020 In addition, the AS + DH + BBR + 3-MA group exhibited a significantly enlarged plaque, substantial foam cell and macrophage infiltration, increased levels of IL-1beta and TNF-alpha, and decreased LC3-II and P62 (P < 0.01) expression when compared to the AS + DH + BBR group. Berberine 27-30 tumor necrosis factor Rattus norvegicus 171-180 32403887-12 2020 Berberine intervention had significantly reduced endotoxin (0.213 +- 0.025) and TNF-alpha level (0.93 +- 0.07) (P < 0.05). Berberine 0-9 tumor necrosis factor Rattus norvegicus 80-89 31958765-8 2020 Moreover, the expression of IL-1beta, IL-6 and TNF-alpha in ileum were suppressed by BBR treatment. Berberine 85-88 tumor necrosis factor Rattus norvegicus 47-56 31360147-13 2019 In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM. Berberine 15-24 tumor necrosis factor Rattus norvegicus 158-167 31701723-9 2019 Compared with VCI group, the escape latency in berberine-treated groups was shortened significantly (P<0.01, P<0.05) and the times of passing through the platform were increased remarkably (P<0.01, P<0.05), the levels of SOD, GSH and 5-HT were increased significantly (P<0.01), while the contents of TNF-alpha, IL-1beta and MAO were decreased remarkably (P<0.01). Berberine 47-56 tumor necrosis factor Rattus norvegicus 300-309 30456649-8 2019 Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6). Berberine 9-18 tumor necrosis factor Rattus norvegicus 159-186 30861392-2 2019 In this study, the results of the in vitro model of immunoglobulin (Ig) E-mediated mast cell degranulation showed that berberine significantly inhibited the release of beta-hexosaminidase (beta-HEX), histamine, IL-4 and TNF-alpha in rat basophilic leukemia cells (RBL-2H3 cells). Berberine 119-128 tumor necrosis factor Rattus norvegicus 220-229 30456649-8 2019 Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6). Berberine 9-18 tumor necrosis factor Rattus norvegicus 188-196 29353208-9 2018 Lower expression of SREBP-1c, pERK, TNF-alpha, and pJNK were also observed in berberine + curcumin group. Berberine 78-87 tumor necrosis factor Rattus norvegicus 36-45 30542485-7 2018 TLR4, NF-kappaB, iNOS, TNF-alpha, IL-6 and IL-10 expression was decreased following berberine intervention. Berberine 84-93 tumor necrosis factor Rattus norvegicus 23-32 29365334-7 2018 Berberine reversed these effects and inhibited LPS-induced TLR4/TNF-alpha activation, resulting in increased insulin receptor and insulin receptor substrate-1 expression in the liver. Berberine 0-9 tumor necrosis factor Rattus norvegicus 64-73 29365334-8 2018 These findings suggested that berberine may reduce insulin resistance, at least in part by modulating the gut microbiota along with inhibiting LPS/TLR4/TNF-alpha signaling in the liver. Berberine 30-39 tumor necrosis factor Rattus norvegicus 152-161 24803296-5 2014 The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P<0.05). Berberine 180-189 tumor necrosis factor Rattus norvegicus 25-58 28068647-2 2017 Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages. Berberine 26-35 tumor necrosis factor Rattus norvegicus 141-168 28068647-2 2017 Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages. Berberine 26-35 tumor necrosis factor Rattus norvegicus 170-178 28068647-6 2017 In addition, the paw edema, pain score, pro-inflammatory cytokines (IL-1beta and TNFalpha) and articular elastase activity were found significantly reduced in berberine (50mg/kgb wt) administered MSU crystal-induced rats. Berberine 159-168 tumor necrosis factor Rattus norvegicus 81-89 25600690-8 2015 Berberine also caused decrease in TNF-alpha level and caspase-3 activity which was higher with HgCl2. Berberine 0-9 tumor necrosis factor Rattus norvegicus 34-43 25605990-5 2015 Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals. Berberine 124-133 tumor necrosis factor Rattus norvegicus 24-51 25605990-5 2015 Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals. Berberine 124-133 tumor necrosis factor Rattus norvegicus 53-62 24744190-3 2014 The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2). Berberine 31-40 tumor necrosis factor Rattus norvegicus 121-148 24744190-3 2014 The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2). Berberine 31-40 tumor necrosis factor Rattus norvegicus 150-159 24744190-3 2014 The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2). Berberine 31-40 tumor necrosis factor Rattus norvegicus 218-227 24676878-7 2014 Results showed significant lower expression of IL-1beta, IL-6, TGF-beta, TNF-alpha, and ICAM-1, in berberine groups compared with the operation group. Berberine 99-108 tumor necrosis factor Rattus norvegicus 73-82 24530556-5 2014 Results showed that the Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level in were significantly lower in berberine treated rats compared to the control animals. Berberine 126-135 tumor necrosis factor Rattus norvegicus 24-51 24530556-5 2014 Results showed that the Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level in were significantly lower in berberine treated rats compared to the control animals. Berberine 126-135 tumor necrosis factor Rattus norvegicus 53-62 25477998-8 2014 Berberine decreased the ST elevation induced by acute myocardial ischemia, and decreased serum levels of CK-MB, LDH, TNF-alpha, and IL-6. Berberine 0-9 tumor necrosis factor Rattus norvegicus 117-126 22382522-0 2013 Berberine inhibits norepinephrine-induced apoptosis in neonatal rat cardiomyocytes via inhibiting ROS-TNF-alpha-caspase signaling pathway. Berberine 0-9 tumor necrosis factor Rattus norvegicus 102-111 20868663-7 2010 Berberine upregulated PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression in adipose tissue, decreased tumor necrosis factor alpha and free fatty acid content and increased lipoprotein lipase activity in serum and adipose tissue. Berberine 0-9 tumor necrosis factor Rattus norvegicus 121-148 23523906-13 2013 Strikingly, berberine exhibited target attenuation of tumor necrosis factor alpha (TNF-alpha) and key pro-fibrotic mediator, transforming growth factor beta 1 (TGF-beta1). Berberine 12-21 tumor necrosis factor Rattus norvegicus 54-81 23523906-13 2013 Strikingly, berberine exhibited target attenuation of tumor necrosis factor alpha (TNF-alpha) and key pro-fibrotic mediator, transforming growth factor beta 1 (TGF-beta1). Berberine 12-21 tumor necrosis factor Rattus norvegicus 83-92 21062898-3 2010 Berberine, a herbal therapeutic agent that has been recently established as a therapy for diabetes and hypercholesterinemia, was able to completely antagonize the TNFalpha-mediated barrier defects in the cell model and in rat colon. Berberine 0-9 tumor necrosis factor Rattus norvegicus 163-171 21062898-6 2010 Berberine alone had no effect while it fully prevented the TNFalpha-induced barrier defects. Berberine 0-9 tumor necrosis factor Rattus norvegicus 59-67 21062898-9 2010 Berberine prevented TNFalpha-induced claudin-1 disassembly and upregulation of claudin-2. Berberine 0-9 tumor necrosis factor Rattus norvegicus 20-28